Targovax Adjusts Clinical Pipeline After ASCO Disrupts TG Vaccine Program

Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its...

More From BioPortfolio on "Targovax Adjusts Clinical Pipeline After ASCO Disrupts TG Vaccine Program"